Do we have clarity on the therapeutic levels of morphine and its metabolites: seeking answers for the dilemma?
In spite of numerous investigations and decades of research, there is still a void in the complete understanding of the therapeutic action of morphine due to the complex nature of its pharmacokinetic/metabolic disposition coupled with elusive pharmacodynamics. This commentary attempts to collate current information on this very important topic and provide perspective to further tease out the relationship between morphine and its metabolites to its purported clinical effect. Similar to numerous acute therapies that need a close vigil for therapy optimization, postoperative pain management with morphine is a challenge due to its extreme intrasubject variability, a fragile therapeutic index, and complex pharmacology interlinked with formation and transport of active metabolite(s). Although numerous investigations of pharmacokinetics and pharmacodynamic effects of morphine and its active glucuronide metabolites have been carried out and excellent data published, still there remains a void in complete understanding of desired therapeutic levels for a meaningful therapeutic outcome without the avoidance of morphine-related side effect profile. The 2009 report of Hammoud et al. (Pain. 2009;144:139-146) confirms the challenges of which one need to be aware during postoperative pain management with morphine in spite of well-controlled intravenous titration using an institutional protocol. These authors have attempted to correlate the plasma concentrations of morphine and its key metabolites, morphine-3-glucuronide (3MG) and morphine-6-glucuronide (6MG), with clinical outcomes such as sedation and adverse effects. This report assumes high significance, since such an investigation to titrate postoperative patients to a fixed desired clinical efficacy outcome has hitherto been not performed in patients who underwent postoperative pain managemnt. Moreover, the intravenous titration option used in the study provided a clean collection of pharmacokinetic surrogate data of morphine along with its metabolites without the issue of absorption and/or oral bioavailability setback if morphine was given by oral route. However, the various pharmacokinetic surrogates used in this study was found insufficient to distinguish the clinical effects. Given the complicated pharmacokinetic and pharmacodynamic profiles of morphine and its metabolites (6MG and 3MG), this commentary provides some thoughts to seek answers for this interesting dilemma.